Clinical Trials

The Hadassah Melanoma and Cancer Immunotherapy Center is continuously involved in international multicenter clinical trials sponsored by pharmaceutical companies developing new drugs for the treatment of metastatic melanoma.

The following clinical trials are recruiting participants:

• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)
  CA209-915
  Sponsor:
  Bristol-Myers Squibb
  
  
• A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
  GO29475
  Sponsor:
  Genentech, Inc.
  
  
• An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
  GO28399
  Sponsor:
  Hoffmann-La Roche
  
  
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
  CO39262
  Sponsor:
  Hoffmann-La Roche
  
  
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
  CPDR001F2301
  Sponsor:
  Novartis Pharmaceuticals